Japan Medical Dynamic Marketing, INC. (FRA:JMD)
Germany · Delayed Price · Currency is EUR 2.540
-0.040 (-1.55%)
At close: Jan 30, 2026
FRA:JMD Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 24,583 | 25,114 | 23,177 | 21,307 | 19,193 | 16,738 | |
Revenue Growth (YoY) | -0.24% | 8.36% | 8.78% | 11.01% | 14.67% | -7.44% |
Cost of Revenue | 9,851 | 9,468 | 8,415 | 7,316 | 6,204 | 5,320 |
Gross Profit | 14,732 | 15,646 | 14,762 | 13,991 | 12,989 | 11,418 |
Selling, General & Admin | 11,557 | 11,530 | 10,631 | 9,809 | 8,443 | 7,443 |
Research & Development | 898.89 | 959 | 874 | 662 | 485 | 466 |
Other Operating Expenses | 43 | 162 | 148 | 146 | 158 | 138 |
Operating Expenses | 13,887 | 14,090 | 13,015 | 11,967 | 10,327 | 9,249 |
Operating Income | 844.48 | 1,556 | 1,747 | 2,024 | 2,662 | 2,169 |
Interest Expense | -174.64 | -75 | -32 | -18 | -30 | -41 |
Earnings From Equity Investments | -58.08 | -56 | -65 | -63 | -12 | - |
Currency Exchange Gain (Loss) | 164.68 | 63 | 190 | 100 | -35 | - |
Other Non Operating Income (Expenses) | -8.36 | 1 | 1 | - | 6 | -4 |
EBT Excluding Unusual Items | 768.08 | 1,489 | 1,841 | 2,043 | 2,591 | 2,124 |
Gain (Loss) on Sale of Investments | - | - | -72 | - | - | - |
Asset Writedown | -41.19 | -52 | -48 | -56 | -87 | -91 |
Legal Settlements | -1,555 | -1,555 | -75 | - | - | - |
Other Unusual Items | -231 | -224 | -11 | -218 | 245 | - |
Pretax Income | -1,059 | -342 | 1,635 | 1,769 | 2,749 | 2,033 |
Income Tax Expense | 9.27 | 126 | 331 | 334 | 608 | 353 |
Earnings From Continuing Operations | -1,068 | -468 | 1,304 | 1,435 | 2,141 | 1,680 |
Minority Interest in Earnings | 15.24 | 7 | -33 | -12 | -6 | -16 |
Net Income | -1,053 | -461 | 1,271 | 1,423 | 2,135 | 1,664 |
Net Income to Common | -1,053 | -461 | 1,271 | 1,423 | 2,135 | 1,664 |
Net Income Growth | - | - | -10.68% | -33.35% | 28.31% | -23.11% |
Shares Outstanding (Basic) | 26 | 26 | 26 | 26 | 26 | 26 |
Shares Outstanding (Diluted) | 26 | 26 | 26 | 26 | 26 | 26 |
Shares Change (YoY) | 0.03% | 0.05% | -0.11% | -0.12% | -0.00% | -0.04% |
EPS (Basic) | -39.98 | -17.51 | 48.29 | 54.00 | 80.92 | 63.07 |
EPS (Diluted) | -39.98 | -17.51 | 48.29 | 54.00 | 80.92 | 63.07 |
EPS Growth | - | - | -10.58% | -33.27% | 28.31% | -23.07% |
Free Cash Flow | - | -505 | 321 | 964 | 1,572 | 1,251 |
Free Cash Flow Per Share | - | -19.18 | 12.20 | 36.58 | 59.58 | 47.41 |
Dividend Per Share | 15.000 | 15.000 | 14.000 | 13.000 | 12.000 | 11.000 |
Dividend Growth | 7.14% | 7.14% | 7.69% | 8.33% | 9.09% | 10.00% |
Gross Margin | 59.93% | 62.30% | 63.69% | 65.66% | 67.68% | 68.22% |
Operating Margin | 3.44% | 6.20% | 7.54% | 9.50% | 13.87% | 12.96% |
Profit Margin | -4.28% | -1.84% | 5.48% | 6.68% | 11.12% | 9.94% |
Free Cash Flow Margin | - | -2.01% | 1.39% | 4.52% | 8.19% | 7.47% |
EBITDA | 2,572 | 3,227 | 3,342 | 3,573 | 4,082 | 3,557 |
EBITDA Margin | 10.46% | 12.85% | 14.42% | 16.77% | 21.27% | 21.25% |
D&A For EBITDA | 1,728 | 1,671 | 1,595 | 1,549 | 1,420 | 1,388 |
EBIT | 844.48 | 1,556 | 1,747 | 2,024 | 2,662 | 2,169 |
EBIT Margin | 3.44% | 6.20% | 7.54% | 9.50% | 13.87% | 12.96% |
Effective Tax Rate | - | - | 20.24% | 18.88% | 22.12% | 17.36% |
Advertising Expenses | - | 197 | 295 | 279 | 220 | 320 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.